Literature DB >> 11742168

Botulinum toxin type-A in therapy of patients with anismus.

Y Ron1, Y Avni, A Lukovetski, J Wardi, D Geva, S Birkenfeld, Z Halpern.   

Abstract

INTRODUCTION: Anismus is a common cause of constipation and outlet obstruction. Standard therapy with laxatives or biofeedback has conflicting results. Surgical treatment gives poor results and has practically been abandoned.
PURPOSE: This study was designed to evaluate the efficacy of botulinum toxin type-A (Botox) injection to the puborectalis muscle in patients with anismus.
METHODS: Twenty-five patients (15 females; mean age, 23.2) with history of constipation and symptoms of outlet obstruction underwent anorectal perfusion manometry and video-proctography. All patients were found to have a nonrelaxing puborectalis muscle on both modalities. All have been unable to expel a rectal balloon. Each patient who participated in the study was randomly assigned to undergo local injection of Botox--10 units to each side of the puborectalis or 20 units to the posterior aspect of this muscle. Eight patients underwent further injections1-5 every 3 months in accordance with previous results. Follow-up was conducted 1, 4, 12, and 24 weeks after injection. Straining, anorectal pain, and overall satisfaction were assessed on a visual analog scale. Weekly evacuation, fecal incontinence, and complications were recorded. At the weekly meeting, each patient underwent anorectal manometry with a balloon expulsion test.
RESULTS: Manometric relaxation was achieved after the first injection in 18 patients (75 percent). Once relaxation was achieved, it lasted throughout the follow-up. Nine patients (37.5 percent) expelled the rectal balloon after the first injection. Seven of 16 patients who failed the first injection had an additional one. In 2 patients it was successful (28.6 percent). Symptom improvement of 29.2 percent in straining index was recorded during follow-up. In 3 patients (12.5 percent) pain developed after injection. No other complications were observed. Overall satisfaction with Botox injection results was observed in 58.3 percent.
CONCLUSIONS: Botox injection to the puborectalis muscle has been found to have a limited therapeutic effect on patients suffering from anismus. Our results justify the need for further double-blind placebo-controlled trials to determine the exact role of botulinum toxin type-A in anismus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742168     DOI: 10.1007/bf02234461

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  28 in total

Review 1.  The use of botulinum toxin for the treatment of gastrointestinal motility disorders.

Authors:  Frank Friedenberg; Satya Gollamudi; Henry P Parkman
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

Review 2.  Treatment strategies in obstructed defecation and fecal incontinence.

Authors:  Marat Khaikin; Steven-D Wexner
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 3.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

4.  Paradoxical puborectalis contraction and increased perineal descent.

Authors:  Ron G Landmann; Steven D Wexner
Journal:  Clin Colon Rectal Surg       Date:  2008-05

Review 5.  Endoscopic botox injections in therapy of refractory gastroparesis.

Authors:  Andrew Ukleja; Kanwarpreet Tandon; Kinchit Shah; Alicia Alvarez
Journal:  World J Gastrointest Endosc       Date:  2015-07-10

Review 6.  The Role of Botox in Colorectal Disorders.

Authors:  Dan Carter; Ram Dickman
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

7.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

8.  Botulinum toxin type-A injection to treat patients with intractable anismus unresponsive to simple biofeedback training.

Authors:  Yong Zhang; Zhen-Ning Wang; Lei He; Ge Gao; Qing Zhai; Zhi-Tao Yin; Xian-Dong Zeng
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

9.  Management of pelvic floor disorders: biofeedback and more.

Authors:  David Prichard; Adil E Bharucha
Journal:  Curr Treat Options Gastroenterol       Date:  2014-12

10.  Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence.

Authors:  Steve Heymen; Yolanda Scarlett; Kenneth Jones; Yehuda Ringel; Douglas Drossman; William E Whitehead
Journal:  Dis Colon Rectum       Date:  2009-10       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.